148 related articles for article (PubMed ID: 25062434)
1. How does the quality of phospholipidosis data influence the predictivity of structural alerts?
Przybylak KR; Alzahrani AR; Cronin MT
J Chem Inf Model; 2014 Aug; 54(8):2224-32. PubMed ID: 25062434
[TBL] [Abstract][Full Text] [Related]
2. Modeling phospholipidosis induction: reliability and warnings.
Goracci L; Ceccarelli M; Bonelli D; Cruciani G
J Chem Inf Model; 2013 Jun; 53(6):1436-46. PubMed ID: 23692521
[TBL] [Abstract][Full Text] [Related]
3. In Silico Studies of the Relationship Between Chemical Structure and Drug Induced Phospholipidosis.
Przybylak KR; Cronin MT
Mol Inform; 2011 May; 30(5):415-29. PubMed ID: 27467088
[TBL] [Abstract][Full Text] [Related]
4. Why are most phospholipidosis inducers also hERG blockers?
Slavov S; Stoyanova-Slavova I; Li S; Zhao J; Huang R; Xia M; Beger R
Arch Toxicol; 2017 Dec; 91(12):3885-3895. PubMed ID: 28551711
[TBL] [Abstract][Full Text] [Related]
5. In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies.
Nioi P; Perry BK; Wang EJ; Gu YZ; Snyder RD
Toxicol Sci; 2007 Sep; 99(1):162-73. PubMed ID: 17567588
[TBL] [Abstract][Full Text] [Related]
6. Predicting in vivo phospholipidosis-inducing potential of drugs by a combined high content screening and in silico modelling approach.
Bauch C; Bevan S; Woodhouse H; Dilworth C; Walker P
Toxicol In Vitro; 2015 Apr; 29(3):621-30. PubMed ID: 25668432
[TBL] [Abstract][Full Text] [Related]
7. Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells.
Atienzar F; Gerets H; Dufrane S; Tilmant K; Cornet M; Dhalluin S; Ruty B; Rose G; Canning M
Toxicol Sci; 2007 Mar; 96(1):101-14. PubMed ID: 17175557
[TBL] [Abstract][Full Text] [Related]
8. Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds.
Hanumegowda UM; Wenke G; Regueiro-Ren A; Yordanova R; Corradi JP; Adams SP
Chem Res Toxicol; 2010 Apr; 23(4):749-55. PubMed ID: 20356072
[TBL] [Abstract][Full Text] [Related]
9. Computational identification of a phospholipidosis toxicophore using (13)C and (15)N NMR-distance based fingerprints.
Slavov SH; Wilkes JG; Buzatu DA; Kruhlak NL; Willard JM; Hanig JP; Beger RD
Bioorg Med Chem; 2014 Dec; 22(23):6706-6714. PubMed ID: 25228124
[TBL] [Abstract][Full Text] [Related]
10. Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Kruhlak NL; Choi SS; Contrera JF; Weaver JL; Willard JM; Hastings KL; Sancilio LF
Toxicol Mech Methods; 2008; 18(2-3):217-27. PubMed ID: 20020916
[TBL] [Abstract][Full Text] [Related]
11. ToxAlerts: a Web server of structural alerts for toxic chemicals and compounds with potential adverse reactions.
Sushko I; Salmina E; Potemkin VA; Poda G; Tetko IV
J Chem Inf Model; 2012 Aug; 52(8):2310-6. PubMed ID: 22876798
[TBL] [Abstract][Full Text] [Related]
12. In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
Fischer H; Atzpodien EA; Csato M; Doessegger L; Lenz B; Schmitt G; Singer T
J Med Chem; 2012 Jan; 55(1):126-39. PubMed ID: 22122484
[TBL] [Abstract][Full Text] [Related]
13. Construction and Consensus Performance of (Q)SAR Models for Predicting Phospholipidosis Using a Dataset of 743 Compounds.
Orogo AM; Choi SS; Minnier BL; Kruhlak NL
Mol Inform; 2012 Oct; 31(10):725-39. PubMed ID: 27476455
[TBL] [Abstract][Full Text] [Related]
14. Relationship between in vitro phospholipidosis assay using HepG2 cells and 2-week toxicity studies in rats.
Miyamoto S; Matsumoto A; Mori I; Horinouchi A
Toxicol Mech Methods; 2009 Oct; 19(8):477-85. PubMed ID: 19793005
[TBL] [Abstract][Full Text] [Related]
15. Comparison of a genomic and a multiplex cell imaging approach for the detection of phospholipidosis.
Tilmant K; Gerets HH; Dhalluin S; Hanon E; Depelchin O; Cossu-Leguille C; Vasseur P; Atienzar FA
Toxicol In Vitro; 2011 Oct; 25(7):1414-24. PubMed ID: 21515356
[TBL] [Abstract][Full Text] [Related]
16. Liposome electrokinetic chromatography based in vitro model for early screening of the drug-induced phospholipidosis risk.
Wang T; Feng Y; Jin X; Fan X; Crommen J; Jiang Z
J Pharm Biomed Anal; 2014 Aug; 96():263-71. PubMed ID: 24814828
[TBL] [Abstract][Full Text] [Related]
17. Use of the Distribution Coefficient in Brain Polar Lipids for the Assessment of Drug-Induced Phospholipidosis Risk.
Ceccarelli M; Wagner B; Alvarez-Sánchez R; Cruciani G; Goracci L
Chem Res Toxicol; 2017 May; 30(5):1145-1156. PubMed ID: 28398727
[TBL] [Abstract][Full Text] [Related]
18. In vitro validation of drug-induced phospholipidosis.
Park S; Choi YJ; Lee BH
J Toxicol Sci; 2012; 37(2):261-7. PubMed ID: 22467016
[TBL] [Abstract][Full Text] [Related]
19. In silico modeling to predict drug-induced phospholipidosis.
Choi SS; Kim JS; Valerio LG; Sadrieh N
Toxicol Appl Pharmacol; 2013 Jun; 269(2):195-204. PubMed ID: 23541745
[TBL] [Abstract][Full Text] [Related]
20. Are hERG channel blockers also phospholipidosis inducers?
Sun H; Xia M; Shahane SA; Jadhav A; Austin CP; Huang R
Bioorg Med Chem Lett; 2013 Aug; 23(16):4587-90. PubMed ID: 23856051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
